FibroGen May Have A New Opening For Roxadustat In The US

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company announced positive Phase II data for roxadustat in chemotherapy-induced anemia.

Two Roads
FibroGen could have another path to take forward for roxadustat • Source: Alamy

Just weeks after FibroGen, Inc.'s lead asset roxadustat failed to win approval from the US Food and Drug Administration for anemia in chronic kidney disease, the company announced positive clinical trial data for the drug in a different indication, chemotherapy-induced anemia. The results of the Phase II WHITNEY trial released on 25 August could provide an opportunity for FibroGen to pivot to the chemotherapy-induced anemia indication in the US.

Earlier in August, FDA issued a complete response letter (CRL) for roxadustat in CKD – a big disappointment for FibroGen...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Blood and Clotting

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone

 
• By Urtė Fultinavičiūtė

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod

 
• By Alaric DeArment

US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.

Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III

 
• By Jessica Merrill

The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.

Abecma Or Bust: 2seventy Sells Final Research Program To Novo

 
• By Jessica Merrill

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.